Minesulin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Minesulin

What is Minesulin?

Minesulin is a medicinal product designed to alleviate symptoms of pain, inflammation, and fever, belonging to the Non-Steroidal Anti-Inflammatory Drug (NSAID) pharmacological class. Its composition and function are focused on modulating the body's inflammatory response at a chemical level, making it a critical agent for symptomatic relief.


Quick Facts

Property Description
Active ingredient Nimesulide (INN)
Form Tablet, granules for oral suspension, gel
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose Relief of pain, inflammation, and fever
Origin Synthetic compound

What Type of Medicine is Minesulin and What is its Active Ingredient?

The core constituent of Minesulin is the active ingredient Nimesulide, which is a synthetic compound classified chemically as a sulfonanilide derivative. Nimesulide is classified as a sulfonamide and an analgesic agent. As an NSAID, Nimesulide is characterized as a preferential Cyclooxygenase-2 (COX-2) inhibitor, a property noted in pharmacological studies, which helps to differentiate its action from non-selective alternatives.

How is Minesulin Classified Pharmacologically?

Pharmacologically, Minesulin is utilized because it aims to reduce the synthesis of prostaglandins, which are chemical messengers directly responsible for propagating pain, tissue inflammation, and elevated body fever. The drug is a non-narcotic agent; its general therapeutic purpose is exclusively centered on providing relief from these acute symptoms. Nimesulide provides an effective option for the treatment of acute pain and primary dysmenorrhea. This action supports the general use of the medicine for easing pain associated with temporary discomfort.

What Forms and General Compositions are Available for Minesulin?

Minesulin is manufactured in several distinct pharmaceutical preparations to facilitate both internal and external application, including tablets and granules for oral suspension for internal action, as well as a gel for cutaneous use. The differentiation lies in the route: the oral forms are designed for systemic effect, where the Nimesulide is distributed throughout the body for generalized relief, whereas the topical gel provides a more focused, localized action. Each preparation is formulated as a single-component product, combining the active Nimesulide with necessary excipients or a hydro-alcoholic gel base.

Regulatory References

  1. EMA Nimesulide Review

What side effects are possible with Minesulin?

The official safety profile for Minesulin (Nimesulide) focuses on risks classified according to their frequency and the body system affected, based on regulatory documentation like the Summary of Product Characteristics (SmPC).

Adverse Reaction Scope

Adverse effects are grouped into system-organ classes, with Hepatobiliary Disorders (liver problems) being a central concern, alongside Gastrointestinal Disorders and Dermatological Reactions.

Frequency Classification (Examples) Adverse Reactions
Common (1/100 to <1/10) Diarrhea, Nausea, Vomiting, transient increases in liver enzyme levels.
Uncommon (1/1,000 to <1/100) Hypertension, Pruritus (itching), Rash, Oedema (fluid retention).
Very Rare (<1/10,000) Acute Liver Failure (including fatal cases), Fulminant Hepatitis, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Anaphylaxis.

Safety Constraints and Special Populations

Serious adverse reactions explicitly documented include acute liver failure, gastrointestinal ulceration/bleeding/perforation, and severe skin reactions. Safety constraints are formally defined in the official labeling:

  • Contraindications: Use is prohibited in patients with a history of hepatotoxic reactions to Nimesulide, active gastric or duodenal ulcers, severe hepatic impairment, or severe renal impairment.
  • Exposure Patterns: Regulatory notes state that liver damage has been reported following short exposure to the medicine, and the risk of serious skin reactions is highest early in the course of therapy.
  • Population Note: Appropriate clinical monitoring is advised for Older Adults, who have an increased susceptibility to adverse effects. The medicine is not recommended for use in children under 12 years of age.

Regulatory Safety Summary

Regulatory documents structure the risk by classifying common, mostly transient, effects separately from very rare, clinically significant outcomes like acute liver failure. This comprehensive safety profile restricts the use of Minesulin based on pre-existing hepatic and GI conditions, guiding its overall use within regulatory limits.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Nimesulide (Minesulin) may present with documented clinical signs that are typically extensions of known adverse effects. Manifestations often include initial gastrointestinal effects such as nausea, vomiting, and epigastric pain, alongside systemic symptoms like lethargy and somnolence.


Immediate Emergency Action

A suspected or confirmed overdose requires the patient to seek immediate medical attention and contact a medical professional or poison control center immediately. Regulatory guidance emphasizes that while the presentation may be mild, acute overdose carries a risk of severe and life-threatening outcomes.


Severe Outcomes and Management

Serious complications documented in regulatory labeling involve major organ systems, including gastrointestinal bleeding, acute renal failure, and hepatic failure. In rare, severe instances, respiratory depression or coma may occur. Management is strictly symptomatic and supportive, as no specific antidote is known for Nimesulide overdose.

Procedural steps recommended within the first four hours after ingestion of a toxic dose may include gastric lavage and activated charcoal. Following ingestion, patients must undergo continuous clinical observation, and monitoring of both renal function and hepatic function is required. Regulatory documentation also notes that elderly patients are particularly vulnerable to NSAID overdose effects.

Therapeutic Uses of Minesulin

What Minesulin Treats: Main Uses and Benefits

Minesulin is applied across domains where additional symptomatic support is needed, primarily focusing on symptoms related to physical discomfort and functional strain. The medication is commonly used to provide symptomatic relief across key therapeutic areas in situations where patients experience these conditions. It helps address symptom clusters that may become intense or disruptive, such as those associated with acute pain, symptomatic relief in painful osteoarthritis flares, and the pain of primary dysmenorrhoea.

The medication is used for managing conditions involving episodic or fluctuating manifestations, including discomfort from minor soft tissue injuries or in the context of dental procedures. It also assists in the management of fever, providing support that helps ease the overall symptom burden when symptoms related to systemic imbalance cluster with physical discomfort.

“The medication is applied when appropriate to offer supportive relief when symptoms interfere with routine activities, contributing to improved comfort during symptomatic periods.”


Quick Fact: Relief for Acute Discomfort
Therapeutic Relevance Situations involving acute pain, symptomatic relief in osteoarthritis, primary dysmenorrhoea, and fever.
Symptom Focus Symptoms related to physical discomfort, systemic imbalance, and increased physiological activity.
Patient Benefit Contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Regulatory References

  1. European Medicines Agency's official summary of product characteristics

Eligibility and Restrictions for Use

Minesulin (Nimesulide) eligibility is strictly defined by regulatory authorities and is generally restricted to use as a second-line treatment for adults and adolescents aged 12 years and older who do not possess any contraindicating conditions.

Contraindications (Must Not Use)

The medicine is strictly contraindicated in several population groups and conditions, including:

  • Children under 12 years of age.
  • Patients with active liver disease or a history of hepatotoxic reactions to Nimesulide.
  • The third trimester of pregnancy and during breastfeeding/lactation.
  • Severe dysfunction of major organs, including severe heart failure and severe renal impairment (creatinine clearance < 30 mL/min).
  • Active peptic ulceration, gastrointestinal haemorrhage, or severe coagulation disorders.
  • Known hypersensitivity to Nimesulide or other NSAIDs.

Restricted Use

Special caution and monitoring are required for older adults and patients with mild to moderate renal impairment. Use is not recommended for women who are attempting to conceive due to the documented potential to impair female fertility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile of Minesulin details constraints primarily related to metabolism and pharmacodynamic risk. Co-administration with other systemic NSAIDs and potentially hepatotoxic substances is restricted due to the heightened risk profile described in regulatory documents.

Pharmacokinetic and Exposure Effects

Minesulin is documented as an inhibitor of the CYP2C9 enzyme, a mechanism that may result in increased plasma concentrations of medicines that are substrates of this pathway. The regulatory label states that Minesulin may significantly elevate serum levels of Lithium and increase the toxicity of Methotrexate. For the latter, a procedural constraint is noted, requiring caution if administration occurs less than 24 hours before or after Minesulin.

Conversely, Minesulin may reduce the diuretic effect of Furosemide, which is noted as requiring special caution in susceptible renal or cardiac patients.

Bleeding and Substance Risk

  • A pharmacodynamic risk of bleeding is documented when Minesulin is combined with anticoagulant agents or acetylsalicylic acid.
  • The use of alcohol abuse must be avoided during treatment, as noted in the regulatory warnings due to the increased risk of hepatic reactions.

Mechanism of Action

The action of Minesulin (Nimesulide) is defined by its ability to precisely modulate specific enzyme systems, leading to a functional change in the body's inflammatory and thermal responses.

Preferential Constraint of COX-2 Activity

The drug's primary action is achieved through the inhibition of the Cyclooxygenase-2 (COX-2) enzyme, which converts Arachidonic Acid into Prostaglandins and other eicosanoids. Minesulin is a preferential inhibitor, demonstrating significantly higher potency against the inducible COX-2 enzyme compared to the constitutive COX-1. This enzymatic constraint modifies early molecular steps within the signaling cascade.

Modulation of Pain and Thermoregulatory Signaling

The reduction in Prostaglandin mathrmE2 (PGE2) concentration impacts key regulatory systems: peripherally, it reduces the sensitization of nociceptors (pain receptors); centrally, it modulates the hypothalamic temperature set-point. This mechanism constrains the formation of mediators, resulting in altered physiological states relevant to the drug's effect profile.

Dosage and Administration Information

How Minesulin is Used

Minesulin (Nimesulide) is utilized based on established guidelines that define the proper method, dose, and duration of use. The fundamental principle for systemic administration is to use the minimum effective dose for the shortest possible duration.

Official Administration Protocol

The medicine is available for both systemic and localized application, depending on the formulation. The standard systemic regimen is defined by specific medical protocols.

Feature Official Instruction
Approved Routes Oral (tablets, granules), Rectal (suppositories), and Topical (gel).
Standard Adult Dose 100 mg per dose.
Maximum Daily Dose 200 mg (100 mg twice daily).
Timing for Oral Forms Must be taken after meals (post cibum).

Duration and Population Constraints

Treatment duration for Minesulin is limited to mitigate potential risks associated with prolonged use. The overall treatment course for oral systemic forms must not exceed 15 consecutive days.

Dosing Rules for Specific Populations:

Systemic formulations are contraindicated in children under 12 years of age and in patients with severe renal (CrCl less than 30 mL/min) or any degree of hepatic impairment. No routine dose adjustment is specified for older adults or adolescents (12–18 years).

Recent Clinical Evidence

Minesulin: Recent Clinical Evidence

Clinical research examining the non-steroidal anti-inflammatory drug (NSAID) Minesulin (nimesulide) has focused primarily on its use for acute pain and primary dysmenorrhea (menstrual pain).


Efficacy Findings

Randomized controlled trials (RCTs) and meta-analyses exploring the effect of Minesulin on acute pain conditions have consistently reported that it produces a greater change in measured outcomes, such as pain reduction, compared to a placebo.

  • Acute Pain: Studies generally report that Minesulin is at least as effective as certain other common NSAIDs (like diclofenac, ibuprofen, and naproxen) for the short-term relief of acute pain.
  • Osteoarthritis: While historically studied for symptomatic relief in osteoarthritis, regulatory bodies have recommended restricting its use, noting that the long-term nature of this condition may increase the potential for adverse effects.

Safety and Risk Profile

Systemic formulations of Minesulin have been subject to several comprehensive safety reviews due to concerns related to hepatotoxicity (liver injury).

  • Liver Risk: The European Medicines Agency (EMA) concluded that the benefits of systemic Minesulin outweigh its risks, provided that its use is strictly limited to short-term treatment (typically a maximum of 15 days) and as a second-line option. This restriction aims to minimize the risk of serious liver-related adverse events.
  • Gastrointestinal Tolerability: Comparative studies suggest that Minesulin is associated with a lower incidence of reported gastrointestinal adverse events, such as ulcers or bleeding, compared to some other non-selective NSAIDs.
  • Study Limitations: Research on its use in high-risk populations, or for extended durations exceeding 15 days, remains limited, reinforcing the need for caution and adherence to prescribed limits.

Key Studies & References

  1. Efficacy of nimesulide in the treatment of primary dysmenorrhea: a systematic review and meta-analysis of randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Minesulin (FAQ)

Q: How quickly does Minesulin start working?

A: Clinical studies and official information indicate that the drug has a relatively fast onset of action. Clinical data supporting the drug's action suggests that a noticeable effect on pain relief may begin as early as 15 minutes following administration.


Q: How long do the effects of Minesulin last?

A: The expected duration of the medicine's effect is generally considered short-term. For continuous symptom control, the official prescribing information indicates a typical interval between doses, suggesting a short half-life. The use of Minesulin is restricted to the shortest time possible.


Q: Does Minesulin interact with alcohol?

A: Regulatory documents list a history of alcoholism as a formal contraindication for Minesulin use. Furthermore, consumption of alcohol is not recommended during treatment due to a heightened risk of adverse reactions, including liver damage, drowsiness, and stomach bleeding.


Q: Can I take Minesulin if I am taking over-the-counter pain relievers?

A: Regulatory labeling states that co-administration with other systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or acetylsalicylic acid is prohibited. This restriction is in place due to a heightened risk of combined adverse effects.


Q: Does taking Minesulin with food reduce the risk of stomach upset?

A: The official administration instructions for Minesulin tablets and granules direct them to be taken after meals (post cibum). This administration instruction is generally intended to help mitigate the potential for gastrointestinal discomfort.


Q: Why is Minesulin only available by prescription?

A: Regulatory authorities limit Minesulin's use because of the potential for serious adverse effects, most notably hepatotoxicity (liver injury). Due to this risk profile, it is restricted to a second-line treatment for acute pain, necessitating use under expert medical supervision.


Q: Can Minesulin cause dependency or withdrawal symptoms?

A: Minesulin is classified as a non-narcotic agent. While official documents contraindicate its use in cases of drug addiction, they do not list dependency or specific withdrawal symptoms among the common or serious adverse reactions.


Q: Can Minesulin be taken on an empty stomach?

A: No. The official instructions for the oral forms (tablets and granules) explicitly state that Minesulin must be taken after meals (post cibum).


Q: Does taking Minesulin cause tiredness or drowsiness?

A: Yes, the official safety profile for Minesulin lists dizziness and somnolence (drowsiness) as potential adverse effects that a patient may experience.


Q: Is it normal to feel nauseous after starting Minesulin?

A: Official regulatory documents list nausea and vomiting as Common adverse reactions. This means that these side effects are known to occur in a larger portion of users (between 1 in 100 and 1 in 10 patients).


Q: Is Minesulin known to cause long-term side effects?

A: Regulatory authorities have restricted the duration of use for systemic Minesulin. Treatment is limited to the shortest time necessary, with an official maximum period of 15 consecutive days, to minimize the potential for serious adverse effects, such as liver injury, which may be associated with prolonged use.


Q: Is Minesulin safe for older adults (seniors)?

A: Minesulin is not formally contraindicated in older adults, and no routine dose reduction is specified. However, official information indicates it should be used with caution due to this population's increased susceptibility to adverse effects. Appropriate clinical monitoring of major organs is noted as necessary for this population.


Q: What happens if I miss a dose of Minesulin?

A: The official product information provides guidance for managing a missed dose. This guidance specifies when a missed dose may be taken and includes a strict warning that the dose should never be doubled to compensate.


Q: Why do official documents say Minesulin has a Black Box Warning?

A: Minesulin is not approved by the U.S. Food and Drug Administration (FDA) and therefore does not carry an FDA Black Box Warning. Regulatory authorities in countries where it is approved address the potential for liver toxicity by mandating strict use limitations, such as the maximum 15-day treatment duration.


Q: Can Minesulin affect my ability to drive?

A: Yes. Because Minesulin can cause central nervous system side effects such as dizziness or somnolence (drowsiness), official product information states it may impair a person's ability to drive or operate heavy machinery. Patients are advised to be aware of how the medicine affects them before performing such activities.


Q: Does Minesulin cause weight gain?

A: Weight gain is not explicitly listed as an adverse reaction in the official safety profile. However, the document does note that Oedema (fluid retention), which can contribute to temporary weight increase, is listed as an Uncommon side effect.


Q: Does Minesulin affect blood pressure?

A: Yes. The official safety profile indicates that Hypertension (high blood pressure) is listed as an Uncommon adverse reaction associated with the use of Minesulin.


Q: Can I crush or split my Minesulin tablet?

A: Minesulin is manufactured in two primary oral forms: tablets (swallowed whole) and granules for oral suspension (designed to be dissolved). Official regulatory product information does not include instructions or approval to crush or split the tablet formulation for administration.


Q: What is the recommended period of time to use Minesulin?

A: The treatment is recommended to be for the shortest possible duration necessary to control acute symptoms, using the minimum effective dose. The total oral treatment course must not exceed 15 consecutive days, which is the regulatory limit.


Q: Is Minesulin described as being well-tolerated?

A: Clinical studies and regulatory reviews have often described Minesulin as a well-tolerated option for short-term relief of acute symptoms. This is often noted alongside its comparatively lower incidence of gastrointestinal adverse events than some other non-selective anti-inflammatory drugs.


Q: Can Minesulin cause headaches?

A: Yes. Headache is listed in the official safety profile as a potential adverse reaction associated with the use of Minesulin.


Q: Are there any specific lifestyle changes mentioned in relation to Minesulin use?

A: The most specific lifestyle constraint mentioned in official warnings is that alcohol abuse must be strictly avoided during the course of treatment. This is due to the potential for an increased risk of hepatic reactions (liver issues).


Q: What happens in the body when Minesulin starts 'working'?

A: Minesulin acts as a preferential inhibitor of the COX-2 enzyme, which reduces the concentration of chemicals called Prostaglandins. This mechanism results in two main effects: it reduces the sensitization of pain signals and modulates the body's central temperature set-point to help ease fever.


Q: Does research show any specific benefits for certain patient groups?

A: Official research focuses on the benefits of Minesulin for specific clinical indications. Studies have primarily examined its effectiveness for the short-term relief of symptoms associated with acute pain and primary dysmenorrhea (severe menstrual pain).

How should Minesulin be stored and disposed of?

How to Store and Dispose of Minesulin

Official regulatory labeling dictates the specific conditions under which Minesulin must be stored to maintain its quality.

Storage Requirement Official Condition
Temperature Store not above 30 C (typically at room temperature, 20 C to 25 C).
Protection Keep in the original container to protect from moisture and light.
Child Safety Store out of the sight and reach of children.

Disposal Instructions

Unused or expired Minesulin should be disposed of via drug take-back programs whenever possible. If a take-back option is not available, the product can be discarded in the household trash. This must be done by first removing the medicine from its original container and mixing it with an undesirable substance (like used coffee grounds or cat litter) before placing the mixture into a sealed bag or container to prevent leakage. The medicine must not be flushed down the toilet or poured into a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Minesulin found in:

A-Z Index: